This Saturday Todos Medical’s (OTCMKTS: TOMDF) CEO set the stage for future international media exposure. This interview was powerful, gripping, and informative and left viewers with a feeling that there really might be a way out of the pandemic. Most of the administration has really given up on fighting COVID-19 and hoping it will burnout, but experts like CEO Gerald Commissiong have been handicapping the pandemic with uncanny accuracy and seems to know better. He believes that the local testing infrastructure coupled with antivirals used at the right time could contain the epidemic. For investors, the interview revealed a massive expansion of the Provista Diagnostics testing program and plans to develop the Tollo test which is expected to detect active infection 1 to 3 days after exposure. To top things off the CEO got in a plug for “very strong data” from the Tollovir trial in the next couple of weeks.
The charts show that investors in Todos have been accumulating shares for quite some time but now the rhetoric about the oral antivirals is starting to resonate. CEO Commissiong claims TOMDF’s Tollovir is next after Molnupiravir and Paxlovid. With less than 10 days until trial results are released on January 27th investors have little time to collect their lottery tickets to a potential multibillion dollar payday. This upcoming binary event could lead to an EUA in Israel and be a mega inflection point for investors.
Investors have seen value inflection points for oral antivirals in the billions. Merck (NYSE: MRK) went up $10 billion on the news and Pfizer (NYSE: PFE) went up $20 billion on the news. The last small pharma player with their drug AT-527 actually failed. Atea Pharmaceuticals (NASDAQ: AVIR) reached $5.0 billion market cap in anticipation of good results. TOMDF is at the same stage as AVIR was prior to their readout except TOMDF has a $60 million market cap, rock solid safety data, and a greater likelihood of working versus the remdesivir look alike. Backing up the CEO’s bravado is extremely strong observational data that saw no deaths in the active arm of severe to critical patients. Add to this PFE’s approval as a 3CL inhibitor, the same target as Todos Medicals Tollovir and the winning lottery tickets may be held by TOMDF shareholders. They have to be in it to win it and the 27th is quickly approaching.
The most interesting dynamic of the interview was when the CEO very cleverly derisked the readout by pointing to the fact that TOMDF’s Tollo test or increased testing in general is precisely what is needed to make the oral antiviral from MRK and PFE effective on a wide scale. If testing increases then TOMDF’s Provista Diagnostics is a huge beneficiary should Tollovir fail. If Tollovir pulls in excellent numbers like expected then MRK and PFE might see TOMDF overtaking them. Regardless of the outcome TOMDF’s technology is of great value to both PFE or MRK setting the stage for a potential bidding war.
The next media exposure for TOMDF might be on a much larger international stage. Investors should closely follow the name into the upcoming readout and might be richly rewarded for investing.
Biden Clip: I’m directing my team to procure an additional half a billion an additional 500 million more tests to distribute for free. I mean a billion tests in total to meet future demand and we’ll continue to work with the retailers and online retailers to increase availability.
Anchor: Welcome back to Saturday agenda that’s President Biden this week announcing the administration would double its order to 1 billion at home COVID tests amid a nationwide shortage. The White House is ramping up efforts to make COVID tests more accessible after facing criticism from both republicans and democrats over the lack of inventory as the highly transmissible omicron variant rips through the country. Joining us now to discuss this is Gerald Commissiong he’s the CEO of one medical company that makes several types of COVID tests. Great to have you with us. What’s the biggest issue now with the testing debacle?
Gerald Commissiong: Well there’s two issues one is the rapid antigen tests that are being used are not very accurate insofar as they don’t detect disease early. So if you take a test today and test negative it doesn’t necessarily mean you have COVID. You could test negative tomorrow or you could test positive tomorrow. There are a couple things related to nose versus throat swabbing and really understanding how to take the swab properly to get an accurate answer. The next thing is obviously we need more PCR testing. So we need to get testing out there at the local level so that you can get those accurate answers very early in the disease course and the reason why that’s important is because we are starting to see some antiviral pills come onto the market. If you want to get one of those pills you need to first test positive. We have our pill Tollovir that is going to be doing a phase two clinical trial readout in a couple of weeks where we’re expecting some very strong data. This will be coming to the market after PAXLOVID by Pfizer and Molnupiravir from Merck. So it’s really important that we get this testing done right so that we can get effective treatments to people early and make sure they don’t end up in the hospital and if they are in the hospital make sure we get them out quickly.
Anchor: Absolutely I’ve had that concern too which is are people doing these tests correctly how accurate are they but uh in the bigger picture is your company going to be assisting in any way with the biden administration and getting more tests out there to the public?
Gerald Commissiong: Oh absolutely. So we have our own lab Provista Diagnostics where we have a capacity upwards of 20 000 tests per day. These are PCR tests, which are highly accurate, means you won’t have to take them over and over and over to get a result and we’re also supplying several labs throughout the country so right now we can probably account for over a hundred thousand tests per day out of our clientele and we intend to ramp that to get up to three or four five hundred thousand tests per day to really expand that capacity. We also are developing a new type of test called the Tollo Test which looks at something called the 3CL protease. That is the exact target of what the Pfizer drug PAXLOVID is going after and our own drug,Tollovir are going after. That has the benefit of potentially catching the disease earlier than PCR and really measuring infectivity which is the big question about when you can be released from quarantine. Am I still infectious? There’s a proxy for that with antigen rapid tests that is not really rooted in good science as of yet. PCR tests can do that but it means you need to take a second PCR test and that’s usually not at home where you measure the ct values. So there’s a real need to understand infectivitiy for quarantine release and we think we can do that with our Tollo Test.
Anchor: That’s really interesting. Is there any merit to reports that the rapid test would be any less effective in detecting Omicron?
Gerald Commissiong: Well it’s not necessarily the rapid tests themselves but how they’re used. If you look at the instructions for use when you get it at your house it tells you to do a nose swab, but we’ve seen on twitter and now there are a number of publications coming out where people are testing negative when you take a nose swab, but positive when you take a throat swab. So we have to change the way we instruct people to take these tests if we want to start to get better results. The practical reality is still that the current tests out on the market, the rapids, the biology is such that it comes one to two to three days after a pcr test so if you start to feel bad and you take a negative you take a rapid test and it shows negative the instructions on the rapid test actually say you should be taking two tests so when you look at this idea that you’re gonna send four tests per household, that’s really only for two people it’s not for four people. So using these tests constantly over and over is going to create some supply chain issues and that’s why we really think having more accessible highly accurate PCR tests with fast turnaround is the solution at the local level to address the problem
Anchor: Yeah it’s all interconnected isn’t it. Supply chain, lack of testing, i think we need those Tik Tokers to give us demonstrations on how to properly self-administer a COVID test. Gerald Commissiong we appreciate you being with us. Thank you.
WHEN INSIDER FINANCIAL HAS A STOCK ALERT, IT CAN PAY TO LISTEN. AFTER ALL, OUR FREE NEWSLETTER HAS FOUND MANY TRIPLE-DIGIT WINNERS FOR OUR SUBSCRIBERS. WE SPECIALIZE IN FINDING MOMENTUM BEFORE IT HAPPENS!
Disclosure: Insider Financial and its owners do not have a position in the stocks posted and have posted this article for free without editorial input. This article was written by a guest contributor and solely reflects his opinions.